Biocon Biologics’ drug substance facilities in Bengaluru get EU GMP certification
PTI, May 12, 2020, 3:16 PM IST
Bengaluru: Biocon on Tuesday said its armBiocon Biologics has receivedEU Good Manufacturing Practice (GMP) certificationfor its biologics drug substance facilities in Bengaluru.
Biocon Biologics India has received the Certificate of GMP compliance fromEuropean Medicines Agency(EMA)represented by the competent authority of Germany for the facilities, the company said in a statement.
These facilities are used for the manufacture of drug substance of Pegfilgrastim and Recombinant human insulin and manufacturing related activities for insulin Glargine and insulin Aspart, it added.
The facilities were inspected by the regulatory agency between January 20-23, 2020, Biocon said.
“This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high quality biosimilars. We remain committed to global standards of quality and compliance,” a company spokesperson said.
Shares of Biocon Ltd were trading at Rs339.90 per scrip on the BSE, down 3.33 per cent from the previous close.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Kotak Mahindra Bank shares tank 13%; mcap erodes by Rs 37,721 crore post RBI action
Four-day market rally makes investors richer by Rs 8.48 lakh crore
Kotak Bank barred from onboarding customers online, issuing fresh credit cards
Reverse migration has begun, says FM Nirmala Sitharaman
Markets sustain winning streak — Sensex jumps over 560 points, Nifty tops 22,300-level
MUST WATCH
Latest Additions
NIA arrests key accused in 2023 attack on Indian High Commission in London
Three persons run over by train in Bengaluru
Indian nationals aboard ‘MSC Aries’ in good health, return delayed due to technicalities: MEA
Husband has no control over wife’s ‘stridhan’: SC
IT sleuths threatening raided leaders to claim money belongs to me, Cong: DK Shivakumar